




Investor Presentation

NASDAQ: BIOX
June 2022

 Bioceres Crop Solutions

Disclaimer

This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or any of its affiliates, and shall not form the basis of any contract, nor shall it be construed in any manner as a commitment on the part of any person to proceed with any transaction. Any reproduction of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of the Company is prohibited. By accepting this Presentation, each recipient agrees to use this Presentation for the sole purpose of evaluating.

Forward-Looking Statements

This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Such forward-looking statements are based on management's reasonable current assumptions, expectations, plans and forecasts regarding the Company's current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management's expectations or could affect the Company's ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the Company's business, operations and financial results and the other factors that are described in the sections entitled "Risk Factors" in the Company's Securities and Exchange Commission filings updated from time to time. Therefore, you should not rely on any of these forward-looking statements. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Industry and Market Data

Unless otherwise noted, the forecasted industry and market data contained in the assumptions for the projections are based upon the Company's management estimates and industry and market publications and surveys. The information from industry and market publications has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. The Company has not independently verified any of the data from third-party sources, nor has the Company ascertained the underlying economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used herein, none of the Company, its affiliates, their respective directors, officers, employees, members, partners, shareholders or agents makes any representation or warranty with respect to the accuracy of such information. These materials are highly sensitive and confidential and being supplied to you solely for your information and for use in this Presentation.

Financial Information Presentation

Historical financial information of Bioceres has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). Investors should note that IFRS differs from generally accepted accounting principles in the United States ("US GAAP"), and investors should consult their own professional advisors for an understanding of the difference between IFRS and US GAAP and how those differences might affect such financial statements.

Use of Non-IFRS Financial Measures

This Presentation includes certain non-IFRS financial measures. These non-IFRS measures are an addition, and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS and neither should be considered as an alternative to net income, operating income or any other performance measures derived in accordance with IFRS or as an alternative to cash flows from operating activities as a measure of our liquidity.

The Company believes that these non-IFRS measures of financial results provide useful supplemental information to investors about the Company and its results. The Company's management uses these non-IFRS measures to evaluate the Company's financial and operating performance and make day-to-day financial and operating decisions. The Company also believes that these non-IFRS measures are helpful to investors because they provide additional information about trends in the Company's core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on its results. However, there are a number of limitations related to the use of these non-IFRS measures and their nearest IFRS equivalents. For example, other companies may calculate non-IFRS measures differently, or may use other measures to calculate their financial performance, and therefore the Company's non-IFRS measures may not be directly comparable to similarly titled measures of other companies.

In this presentation, we discuss non-IFRS measures as forward-looking non-IFRS measures.


Copyrights and Trademarks

All materials contained in this Presentation are protected by copyright laws and may not be reproduced, republished, distributed, transmitted, displayed, broadcast or otherwise exploited in any manner. This Presentation contains trademarks, service marks, and trade names belonging to the Company, its affiliates and other entities and cannot be used without express written consent. Trademarks, service marks, copyrights and trade names referred to in this Presentation, including logos, may appear without the ®, © or TM symbols, but the lack of such symbols is not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other entities' trademarks, service marks, copyrighted material or trade names to imply a relationship or affiliation with, or endorsement or sponsorship of, the Company by any other entities or persons.

Corporate Overview

We are a fully-integrated provider of crop productivity technologies designed to enable the transition of agriculture towards **carbon neutrality**

A Compelling Biotech Story



Growers

Developing technologies that improve crop productivity while preserving environmental resources




Consumers

Grains produced with an improved environmental footprint in partnership with select processors to achieve farm to fork traceability

History

44 years of experience utilizing multiple technological approaches to develop and commercialize products that enhance crop quality and productivity



¹ Historical figures previous to Bioceres Crop Solutions creation on March 2019 represents pro-forma unaudited revenues as if the Rizobacter operation would have been acquired at the start of 2001

² Financials presented for 2020 correspond to Comparable financials for FY20 ended June 30th, 2020

³ Financials presented for 2021 correspond to Comparable financials for FY21 ended June 30th, 2021

Snapshot

Leading positions and **multiple growth levers**

By the numbers

\$287.5M




Revenues¹

- 1st to achieve drought-tolerant wheat and soy
- 23% market share in soybean biologicals

\$61.3M

Adj. EBITDA²

- 200+ patents and patents applications
- 700+ trademarks/applications
- 400+ registered products
- 500+ total employees
- 31+ countries with commercial presence

Operational Business Segments	Revenue & Gross Margin ¹	Main Growth Lever
 Crop Protection	\$159.7M 35%	Adjuvant expansion - Brazil
 Crop Nutrition	\$93.6M 53%	Ramp-up of installed capacity
 Seed and Integrated Products	\$34.3M 63%	HB4

MOMENTIVE™

DE SANGOSSE



syngenta



DONMARIO

TMG

VALENT BIOSCIENCES


¹ Financials presented correspond to Comparable financials for LTM 3Q22 (ended March 31, 2021)

² Financials presented correspond to As Reported Adj. EBITDA, excluding HB4 pre-launch cost, for LTM 3Q22 (ended March 31, 2021)

Agriculture and Climate Change

We will need 2.1x planets by 2050

Contribution to Green House Gas Emissions¹



Effects of climate change on Agriculture

- Projections for 2050 indicate crop yields to drop more than 10%²
- Lower yields result in grain with larger carbon footprint. Improving farming practices reduces the carbon footprint of crops³
- Crop water availability is among the most important yield limiting factors in dryland agriculture

There is a pressing need for the **'sustainable intensification'** of global agriculture in which yields are increased without adverse environmental impact and without the cultivation of more land⁴

¹ IPCC report 2014.

² Challinor AJ, Watson J, Lobell DB, Howden SM, Smith DR, Chhetri N. 2014. "A meta-analysis of crop yield under climate change and adaptation". Nature Climate Change 4: 287-291. IPCC report, 2014.

³ Improving farming practices reduces the carbon footprint of spring wheat production. Nature Communications, 2014.

⁴ Reaping the benefits: science and the sustainable intensification of global agriculture. The Royal Society, October 2009.

The HB4 Technology Performance

The only available technology for drought tolerance in soy-wheat cropping systems

Soy 



+13% impact in yields


Wheat 







+19.5% impact in yields

HB4 Value Creation to Growers

Total addressable market



	Additional value created by HB4 ¹	Total Addressable Market ²	Share of Total Market ³
 Soy	High  Low	~30-35M ha	~35-40%
 Wheat	High  Low	~2.5-3M ha	~30-35%


¹ Analysis comprise average historical HB4 yield improvement extrapolated by county, for each country, and the average commodity prices for the corresponding years

² Defined by HB4 tech fee

³ Total Market defined as total planted hectares(ha) in US, Brazil and Argentina. US: 35M Soy planted ha (average 2015-2020, United States Department of Agriculture USDA). Brazil: 35M Soy and 2M Wheat planted ha (average 2016-2020, Brazilian Institute of Geography and Statistics IBGE). Argentina: 18M Soy and 6M Wheat planted ha (average 2015-2019, Ministry of Agroindustry of Argentina)











HB4 Market Access and Regulatory Status













 Submission

 Approval
Production - Food&Feed

Soy













	Uruguay	
	Bolivia	
	India	
	EU	
	Malaysia	

	Argentina	
	USA	
	Brazil	
	Paraguay	
	Canada	
	China ¹	

Wheat



	Uruguay	
	Paraguay	
	USA	
	Chile	
	Indonesia	
	South Africa	

	Argentina	
	Brazil ¹	
	Colombia ¹	
	Australia ²	
	New Zealand ²	

Regulatory approval in over **85% of the global soy market** (AR, BR, CA and US)



First approval for drought tolerance events in wheat




The company received HB4 Soy approval from China on April 29th, 2022

¹ Food&Feed approval.

² Food Standards Australia New Zealand (FSANZ) has notified the HB4 Wheat Approval Report on May 6th, 2022, considering HB4 Wheat to be safe for Food & Feed

The Integrated Seed Product Concept



- **HB4 Drought tolerance technology**
- **Customized microbial solutions**
- **Top tier germplasm**
- **Digital solutions**

The HB4 Program

Identity preserved production system to multiply HB4 seeds with **selected growers**

1.

Outsource **farming activities** to grow HB4 seeds

2.

Contribute goods¹ into the multiplication agreement

3.

Purchase of total seed production & **quality check**

Designed to further evaluate performance, determine product positioning, and showcase the technology

¹Under these agreements, Bioceres contributes EcoSeed and the other goods to growers for a pre-agreed price (based on prevailing market prices), which are deducted from the service fees paid to growers at the time of harvest for the seed multiplication services provided.

Scalable Sustainability

The Program establishes good agricultural practices for growers, which enhanced by our technologies, significantly contribute to the transition of agriculture towards carbon neutrality

-  Crop rotation ----- **Wheat - Soy**
-  Water & CO₂ management ----- **HB4**
-  Soil conservation --- **No-till**
-  Crop nutrition ----- **Customized microbial solutions + microbeaded fertilizers**
-  Crop protection ---- **Biologicals + high performance adjuvants and molecules**
-  Traceability ----- **Digital monitoring & scouting tools + Blockchain**
-  Farm practices ----- **ASC Certified  Aapresid**

Grower- and consumer-oriented solutions strongly backed by Digital Technologies

Grower

Consumer

Tracking productivity and environmental KPIs for real time decision making

Productivity and quality traits development + biological customized solutions

Smart contracts

Crop monitoring & Inventory surveillance tools

Big data gathering & analytics

Blockchain tracking token

Full visibility on low C-footprint farming practices & grain processing

Increased sustainable and nutritional enriched food portfolio

Farm to fork traceability

HB4 Program Update



Wheat

~53K Hectares Harvested

\$6.4M Contributed goods¹

42% Gross Margin

225 Growers

350 Sites

3
1st Gen Varieties

4
2nd Gen Varieties

Upcoming Season

~\$10-12M

Estimated revenues²



Soybean

~23K Hectares Planted

\$2.0M Contributed goods¹

42% Gross Margin

102 Growers

195 Sites

3
2nd Gen Varieties

9
3rd Gen Varieties

Harvest Season in the Southern Hemisphere


¹ Contributed goods are not included in the quarterly or LTM revenues and, will be recognized as such, once inventories are sold. Metric will be used to account for and track the underlying economic performance of our HB4 Wheat and HB4 Soy Program ahead of reporting HB4 revenues and related accounting measures. By publishing the level of contributed goods, the investment community can also use this information to better gauge our progress.

² Subject to PVP registrations required for invoicing


Company Performance

Proven track-record in delivering **solid financial performance**

Revenues (\$M)



Adjusted EBITDA (\$M)



Adjusted EBITDA Margin (%)



¹ Financials presented correspond to As Reported financials for LTM 3Q22 (ended March 31, 2021). LTM 3Q22 Adjusted EBITDA accounts for: HB4 program pre-operational expenses ahead of booking corresponding sales and profits and profitability erosion from temporary unfavorable FX and inflation dynamics in Arg on a YoY comparison basis.

Balance Sheet and Cash Position

Net Debt

LTM Adj. EBITDA

2.89x



2.61x

2.74x

2.66x

3.06x

2.38x



Notes:

1) Net Debt = Total financial debt less cash and equivalents.

2) Cash & Equivalents includes other cash management short-term investments.

3) LTM financial expenses includes net of gains/losses from translation effects on Argentine Peso denominated loans held by Rizobacter as part of the Company's financial hedging strategy.

4) Pro forma numbers contemplate the conversion of 75% of the 2019 convertible notes on April 1st, 2022.



Exhibits


Unaudited Consolidated Statement of Comprehensive Income

	Three-month period ended 03/31/2022	Three-month period ended 03/31/2021	Nine-month period ended 03/31/2022	Nine-month period ended 03/31/2021
Total revenue	69,482,518	36,221,113	229,051,616	127,315,064
Cost of sales	(45,823,445)	(20,901,909)	(139,038,887)	(69,088,393)
Gross profit	23,659,073	15,319,204	90,012,729	58,226,671
<i>% Gross profit</i>	<i>34%</i>	<i>42%</i>	<i>39%</i>	<i>46%</i>
Operating expenses	(19,869,946)	(11,656,378)	(57,683,281)	(35,107,369)
Share of profit of JV	(203,954)	906,241	715,133	1,211,928
Other income or expenses, net	(1,437,718)	205,127	(3,155,700)	345,449
Operating profit	2,147,455	4,774,194	29,888,881	24,676,679
Finance result	(4,784,248)	(5,008,002)	(18,185,537)	(23,640,338)
Profit before income tax	(2,636,793)	(233,808)	11,703,344	1,036,341
Income tax	(4,340,156)	(390,710)	(11,076,571)	(6,232,163)
Profit / (Loss) for the period	(6,976,949)	(624,518)	626,773	(5,195,822)
Other comprehensive profit / (loss)	12,367,795	1,911,937	25,990,283	2,707,064
Total comprehensive Profit / (Loss)	5,390,846	1,287,419	26,617,056	(2,488,758)
Profit / (loss) for the period attributable to:				
Equity holders of the parent	(6,486,721)	(1,180,484)	(2,185,491)	(7,503,849)
Non-controlling interests	(490,228)	555,966	2,812,264	2,308,027
	(6,976,949)	(624,518)	626,773	(5,195,822)
Total comprehensive profit / (loss) attributable to:				
Equity holders of the parent	3,889,873	510,325	19,685,934	(5,278,946)
Non-controlling interests	1,500,973	777,094	6,931,122	2,790,188
	5,390,846	1,287,419	26,617,056	(2,488,758)




















Unaudited Consolidated Statement of Financial Position

ASSETS	03/31/2022	06/30/2021	LIABILITIES	03/31/2022	06/30/2021
CURRENT ASSETS			CURRENT LIABILITIES		
Cash and cash equivalents	39,041,287	36,046,113	Trade and other payables	123,224,013	72,091,408
Other financial assets	2,243,803	11,161,398	Borrowings	76,364,127	76,785,857
Trade receivables	113,388,127	88,784,172	Employee benefits and social security	6,600,609	4,680,078
Other receivables	16,457,851	11,153,705	Deferred revenue and advances from customers	2,655,322	6,277,313
Income and minimum presumed income taxes recoverable	1,272,791	990,881	Income tax payable	5,970,572	7,452,891
Inventories	102,350,569	61,037,551	Convertible notes	37,578,030	-
Biological assets	22,199,193	2,315,838	Lease liabilities	838,776	750,308
Total current assets	296,953,621	211,489,658	Total current liabilities	253,231,449	168,037,855
NON-CURRENT ASSETS			NON-CURRENT LIABILITIES		
Other financial assets	859,981	1,097,462	Borrowings	78,155,343	47,988,468
Trade receivables	634,428	135,739	Government grants	-	784
Other receivables	1,964,822	2,543,142	Investments in joint ventures and associates	449,943	1,278,250
Income and minimum presumed income taxes recoverable	39,349	12,589	Deferred tax liabilities	27,991,379	25,699,495
Deferred tax assets	4,582,941	3,278,370	Provisions	507,219	449,847
Investments in joint ventures and associates	35,783,222	30,657,173	Consideration for acquisitions	12,747,736	11,790,533
Property, plant and equipment	50,656,642	47,954,596	Convertible notes	12,895,578	48,664,012
Intangible assets	75,714,907	67,342,362	Lease liability	539,935	390,409
Goodwill	34,688,835	28,751,206	Total non-current liabilities	133,287,133	136,261,798
Right-of-use leased asset	1,700,405	1,327,660	Total liabilities	386,518,582	304,299,653
Total non-current assets	206,625,532	183,100,299	EQUITY		
Total assets	503,579,153	394,589,957	Equity attributable to owners of the parent	88,306,816	67,743,242
			Non-controlling interests	28,753,755	22,547,062
			Total equity	117,060,571	90,290,304
			Total equity and liabilities	503,579,153	394,589,957

Main Corporate Entities



Product Portfolio

Segment	Crop Protection		Crop Nutrition		Seed and Integrated Products	
Subsegments	Adjuvants	Insecticides & Fungicides	Inoculants & Biofertilizers	Micro-beaded Fertilizers	Seed Treatments	Seed Traits & Germplasm
Products description	<ul style="list-style-type: none"> • Increase effectiveness and reduce application rates of active ingredients 	<ul style="list-style-type: none"> • Full range of pest control molecules and biocontrol products 	<ul style="list-style-type: none"> • Nitrogen-fixing biologicals that promote growth and replace chemical nutrition sources 	<ul style="list-style-type: none"> • Micro-beaded fertilizers that reduce application rates by promoting efficiency and accuracy 	<ul style="list-style-type: none"> • Full seed treatment packs promote plant growth & reduce chemical nutrition requirements 	<ul style="list-style-type: none"> • EcoSoy and EcoWheat • Improving yields by increasing tolerance to abiotic stress
Insignia products	    		    	    	 	

IP Asset Portfolio

A well-developed and strong portfolio of patents, trademarks and plant variety protections

Patents	<p>214</p> <p>Patents and applications as holder or licensee, exclusively or non-exclusively link to traits</p> <p>Traits include improved yield, drought tolerance, NUE, WUE and TREF technologies, delayed senescence, herbicide resistance, reduced lignin technology and molecular farming technology</p>	<p>49</p> <p>Genes currently protected by own patents and applications</p>	<p>165</p> <p>Licenses link to crop-related traits for use in our products</p>
	<p>126</p> <p>Owned and/or licensee, registered (or in process) crop varieties in Argentina</p> <p>60 in Soybean (13 registered, 47 in registration) 36 in Wheat (29 registered, 7 in registration) 22 in Alfalfa (22 registered) 4 in Corn (4 registered) 2 in Sunflower (2 registered) 2 in Amaranth (2 in registration)</p>	<p>18</p> <p>International varieties registered</p>	<p>15 in Uruguay (10 soybean, 5 wheat) 1 in Paraguay (1 soybean) 1 in South Africa (1 soybean) 1 in Bolivia (1 soybean, X wheat)</p>
Trademarks	<p>46</p> <p>Trademarks in Argentina, Brazil, United States and Uruguay for Bioceres</p>	<p>355</p> <p>Trademarks and applications in Argentina for Rizobacter products</p>	<p>300</p> <p>Trademarks and applications in Brazil, China, United States, Uruguay, Turkey, Pakistan, Paraguay, Peru, Mexico, Colombia, Chile, Canada, Bolivia, South Africa, India, and the EU for Rizobacter products</p>

Diversified Infrastructure Portfolio

Limited Capex Requirements Reflects Well-Invested Asset Base

Crop protection



- Operational capabilities in Argentina and Brazil for production of high- tech adjuvants
- 5 million gallon formulation plant

Crop nutrition



- Fully operational 50,000 ton micro beaded fertilizer plant
- 24,000 gallon fermentation plant and 375,000 square feet of warehouse space for packaging and logistics

Seed and integrated products



- Proprietary brands in leading seed treatment packs
- Field station – 28 hectare (70 acre) research farm in Pergamino, Argentina

Significant realized investments in **modern production capacity** R&D backed by patents, brands and product **registration** in several countries, provides a solid platform to support continued organic growth



Federico Trucco, Chief Executive Officer

Federico is the son of Víctor Trucco and María Cristina Fossaroli, both descending from Italian immigrants that settled as farmers in the central-south region of Santa Fe province. He originally joined Bioceres as a research leader for one of its R&D projects, then a project management firm in the ag-biotech space. Federico then helped organize and initially run Bioceres' biotech center, a state-of-the-art technology incubator called INDEAR. In 2011 he became the first formal CEO of Bioceres. In 2018 Federico was recognized with the Konex award for business innovation for the period 2008-2018, one of Argentina's most prestigious leadership awards. He was also recognized with the EY Entrepreneur of the Year Award for Argentina in 2019. Federico is a biochemist with a Ph.D. degree in Crop Sciences from the University of Illinois at Urbana-Champaign.



Enrique López Lecube, Chief Financial Officer

Enrique received an Industrial Engineering degree from ITBA (Instituto Tecnológico de Buenos Aires) and an MBA from the Kellogg School of Management, at Northwestern University. His career in the last 15 years has been in the field of agribusiness, in leading companies in the sector such as Adeco Agro, Cargill, Lartirigoyen and Bioceres. He has a solid track record in sales, trading and corporate positions in grain, dairy, ag-input, and biotech businesses. He is currently the CFO of Bioceres (since 2017), where he leads initiatives related to M&A, capital markets and investor relations, strategy and corporate development, and business development.



Gerónimo Watson, Chief Technology Officer

Gerónimo Watson previously served in several positions at INDEAR, including as director of product development from 2011 to 2014, head of technology testing and field operations until 2011 and as a member of the Amaranth project starting in 2005. Mr. Watson also serves as a director of Trigall and Verdeca and as chief technology officer of Bioceres, Inc. Mr. Watson received a master's degree in agronomy from the Kansas State University and a degree in agronomy from the Catholic University of Cordoba, Argentina.



Jorge Wagner, Chief Operating Officer

Jorge has also served as chief financial officer of Rizobacter since 2013. Prior to that, he served as regional chief financial officer (Paraguay, Uruguay, Argentina and Bolivia) of Syngenta Agro S.A. from 2010 to 2013. He received a CPA and an MBA from the University of Buenos Aires, Argentina.



Contact Us

Investor Relations

Investorrelations@biocerescrops.com

(54) 0341 4861100

Investors.biocerescrops.com

 Bioceres Crop Solutions